➤ Subscribe for Complete Access

Flexible subscription options to meet your unique needs…

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: November 27, 2021

DrugPatentWatch Database Preview

Details for Patent: 10,286,029

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,286,029 protect, and when does it expire?

Patent 10,286,029 protects MAVYRET and is included in two NDAs.

Protection for MAVYRET has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has one hundred and two patent family members in twenty-five countries.

Summary for Patent: 10,286,029
Title:Method for treating HCV
Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
Inventor(s): Awni; Walid M. (Green Oaks, IL), Bernstein; Barry M. (Mequon, WI), Campbell; Andrew L. (Lake Forest, IL), Dutta; Sandeep (Lincolnshire, IL), Lin; Chih-Wei (Vernon Hills, IL), Liu; Wei (Mundelein, IL), Menon; Rajeev M. (Buffalo Grove, IL), Podsadecki; Thomas J. (Chicago, IL), Wang; Tianli (Lake Bluff, IL), Mensing; Sven (Mannheim, DE)
Assignee: AbbVie Inc. (North Chicago, IL)
Application Number:14/676,370
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 10,286,029

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie Inc MAVYRET glecaprevir; pibrentasvir PELLETS;ORAL 215110-001 Jun 10, 2021 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Abbvie Inc MAVYRET glecaprevir; pibrentasvir TABLET;ORAL 209394-001 Aug 3, 2017 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.